Bibliography
- Das DK, Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 2006;6:36-47
- Le Corre L, Chalabi N, Delort L, et al. Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res 2005;49:462-71
- Das S, Das DK. Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets 2007;6:168-73
- Pervaiz S. Resveratrol-from the bottle to the bedside? Leuk Lymphoma 2001;40:491-8
- Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005;49:472-81
- Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;75:218-20
- Tessitore L, Davit A, Sarotto I, et al. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21CIP expression. Carcinogenesis 2000;21:1619-22
- Yu C, Shin YG, Chow A, et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res 2002;19:1907-14
- Marier JF, Vachon P, Gritsas A, et al. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002;302:369-73
- Kuhnle G, Spencer JP, Chowrimootoo G, et al. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochim Biophys Res Commun 2000;272:212-17
- Amri A, Chaumeil J, Sfar S, et al. Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release 2012;158:182-93
- Basavaraj S, Benson HAE, Brown DH, et al. Novel formulation strategies to improve solubility and pharmacokinetic profile of Resveratrol. Controlled Release Society, product development forum, poorly soluble drugs. CRS, St. Paul, MN, USA; 2011
- Gokce EH, Korkmaz E, Dellera E, et al. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int J Nanomedicine 2012;7:1841
- Neves AR, Lúcio M, Martins S, et al. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine 2013;8:177
- Carlotti ME, Sapino S, Ugazio E, et al. Resveratrol in solid lipid nanoparticles. J Disper Sci Technol 2012;33:465-71
- Narayanan NK, Nargi D, Randolph C, et al. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 2009;125:1-8
- Boocock DJ, Patel KR, Faust GE, et al. Quantitation of trans resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2007;848:182-7
- Basavaraj S, Benson HAE, Brown DH, et al. Application of solvent influenced fluorescence-quenching and enhancement to develop a highly sensitive HPLC methodology for analysis of resveratrol-PEG conjugates. Curr Pharm Anal 2013;9:199-07
- Resveratrol product information. Available from: http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Product_Information_Sheet/1/r5010pis.Par.0001.File.tmp/r5010pis.pdf [Last accessed on 13 May 2013]
- Ariën A, Henry-Toulmé N, Dupuy B. Calcitonin-loaded liposomes: stability under acidic conditions and bile salts-induced disruption resulting in calcitonin-phospholipid complex formation. Biochim Biophys Acta 1994;1193:93-00
- Hu S, Niu M, Hu F, et al. Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int J Pharm 2013;443:693-00
- Rowland RN, Woodley JF. The stability of liposomes in vitro to pH, bile salts and pancreatic lipase. Biochim Biophys Acta 1980;620:400-9
- Rogers JA, Betageri GV, Choi YW. Solubilization of liposomes by weak electrolyte drugs. I. Propranolol. Pharm Res 1990;7:957-61
- Charman WCN, Stella VJ. Lymphatic transport of drugs. CRC Press I LLC; 1992. p. 21-62
- Chia-Ming C, Weiner N. Gastrointestinal uptake of liposomes. I. In vitro and in situ studies. Int J Pharm 1987;37:75-85